This document is an equity research report by Brookline Capital Markets on Veru, Inc., a biopharmaceutical company focusing on urology and oncology products. The report initiates coverage with a 'Buy' rating and a target price of $10.00. It discusses Veru's product pipeline, including Tamsulosin DRS and XR for BPH, Solifenacin DRG for overactive bladder, and VERU-944 for hot flashes in prostate cancer patients. The report includes financial projections, market analysis, and potential risks.
documents/EFTA00810576.pdf
{}